Amgen Inc. has announced the initiation of a Phase 3 clinical program for maridebart cafraglutide (MariTide), an investigational therapy aimed at treating obesity and related conditions. This development follows positive results from a Phase 2 study, which demonstrated promising outcomes in weight loss. MariTide employs a unique mechanism by blocking the GIPR pathway and activating the GLP-1 receptor, a strategy grounded in both preclinical and human genetic research. The company continues to explore the biological pathways involved in obesity through its subsidiary, deCODE genetics, to refine and enhance therapeutic approaches. Further details on the Phase 3 program are anticipated in future communications from Amgen.